Fluticasone propionate has been approved in the United States and in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


fluticasone_propionate studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
105814 IV A post-marketing surveillance to monitor the safety of Flixotide (fluticasone propionate) administered in Korean subjects according to the prescribing information
105815 IV A post-marketing surveillance to monitor the safety of Flixotide Nebules™ (nebulised fluticasone propionate) administered in Korean subjects according to the prescribing information.
EPI40204 IV The use of inhaled corticosteroids and risk of non-vertebral fracture among COPD patients in the UK General Research Practice Database: a nested case-control study
EPI40205 IV A Case-Control Study of the Exposure-Specific Incidence of Fracture with a Focus on Fluticasone Propionate
EPI40206 IV Inhaled corticosteroid use in COPD and the risk of fracture
EPI40207 IV Assessment of the Risk of Non-vertebral Fractures Associated with Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease Patients in the VA
EPI40288 / WEUK199 IV Survival Among COPD Patients Using Fluticasone Priopionate/Salmeterol in Combination versus Other Inhaled Steroids and Bronchdilators Alone
EPIP160 IV A modified prescription-event monitoring study to assess the introduction of Flixotide EvohalerTM into general practice in England
FAS106533 IV A repeat-dose, open-label, 2-session study to assess the systemic exposure to, and pharmacodynamics of, fluticasone propionate HFA inhalation aerosol 88 mcg administered twice-daily for 28 days delivered via an MDI and valved holding chamber with infant face mask to subjects ages 6 months to <12 months who have experienced 2 or more wheezing episodes in the preceding 6 months
FAS40017 IV A double blind, randomised, parallel group study with Flixotide Diskus (250microg) bd and Pulmicort Turbohaler (400microg) bd to compare lowest effective maintenance doses followed by an open health economic evaluation.
FAS40019 IV A single centre, randomized, double-blind, double-dummy, crossover study to determine if the total lung deposition of fluticasone propionate is affected by the delivery system (pressurised metered dose inhaler with VOLUMATICTM or the DISKUSTM inhaler) in children aged 12 – 15 years old with asthma, or by age (comparison with unblended DISKUS treatment of 3 – 4 years old with asthma).
FCO 30002 IV A multicentre, randomised, placebo-controlled, double-blind comparison with 3 parallel groups to investigate the efficacy and safety of inhaled glucocorticoid Fluticasone (500 µg bd via Diskus™) vs. oral glucocorticoid therapy vs. placebo in subjects with chronic obstructive airway disease (COPD) under therapy with Salmeterol (50 µg bd)
FLD-220 IV A Randomized, Double-Blind, Parallel-Group, Comparative Trial Assessing the Long Term Safety of Inhaled Fluticasone Propionate RotadisksŇ Via DiskhalerŇ 50mcg BID and 100mcg BID Versus Placebo in Patients Aged 4 to 11 Years with Mild to Moderate Chronic Asthma
FLD40001 IV A randomised double-blind, active-controlled study to compare the systemic effects of fluticasone propionate ointment 0.005%, mometasone furoate ointment 0.1% and placebo ointment applied under occlusion for 5 days in healthy volunteers
FLD40002 IV A Comparative evaluation of the atrophogenic potential of fluticasone propionate ointment 0.005%, mometasone furoate ointment 0.1% and hydrocortisone ointment 1% in healthy volunteers.
FLIC12 IV A multicentre, blinded, parallel group, randomized study to compare the efficacy and tolerability of nebulised Fluticasone propionate 0.25mg administered twice daily versus nebulised Budesonide 0.5mg administered twice daily in children with mild asthma..
FLIQ50 IV The therapeutic ratio of inhaled corticosteroids in adult asthma: A dose-range comparison between fluticasone propionate and budesonide measuring their effect on bronchial hyperresponsiveness and adrenal cortex function.
FLIQ51 / DENB3002 / (FAS400012) IV A Single-Centre, Double-Blind, Randomised 5 Years Parallel-Group Study Comparing Adjusted Dosing of Inhaled Fluticasone Propionate With Inhaled Placebo Both Administered by Metered Dose Inhaler via a Babyhaler.
FLIQ96 IV (Inhaled Fluticasone propionate in induced sputum study) Effect of fourteen weeks treatment with fluticasone propionate step-down dosing from 1000mcg/day in comparison with a fixed dose of 200mcg/day followed by an open phase with placebo administered for 8 weeks in subjects with mild asthma who exacerbate during treatment with beta-2 agonist (prn).
FLIS02 IV A single-centre, placebo-controlled, randomised, double-blind, double-dummy, cross-over study to investigate longitudinal growth using knemometry in children with mild asthma during treatment with budesonide (200µg/ day and 400µg/ day) and fluticasone propionate (200µg/ day and 400µg/ day) as dry powders
FLIT01 IV Study to Assess Long-Term Tolerability and Safety of Fluticasone Propionate in Severe Chronic Asthma
FLIT69 IV A Multi-centre, Randomised, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Fluticasone Propionate 100µg bd (200µg Daily) Produced by Two Recrystallisation Processes (“Old Process” “New Process”) Administered Via Dry Powder Inhaler, and With “New Process” Fluticasone Propionate 100µg bd (200µg Daily) Via the Pressurised Inhaler in Adult Patients with Chronic Asthma
FLIT81 IV A single-centre, double-blind, cross-over study to investigate adrenal function in asthmatic children receiving treatment with inhaled beclomethasone dipropionate, 400µg/M2 or more daily, compared to half the dose of fluticasone propionate.
FLN-401 IV A double-blind, double-dummy, randomized, parallel group comparison of the efficacy and safety of fluticasone propionate aqueous nasal spray 200mcg QD versus terfenadine 60mg BID versus placebo for two weeks in patients with seasonal allergic rhinitis in the mountain cedar season.
FLN-403 IV The effects of fluticasone propionate aqueous nasal spray vs terfenadine tablets on the nasal mucosa: a one year nasal biopsy study in patients with perennial allergic rhinitis
FLN-411 IV A double-blind, double-dummy, randomized, parallel group comparison of the efficacy and safety of fluticasone propionate aqueous nasal spray 200mcg QD versus astemizole 10mg QD versus placebo for two weeks in patients with seasonal allergic rhinitis
FLN-412 IV A double-blind, double-dummy, randomized, parallel group comparison of the efficacy and safety of fluticasone propionate aqueous nasal spray 200mcg QD versus astemizole 10mg QD versus placebo for four weeks in patients with seasonal allergic rhinitis
FLN-442 IV A double-blind, placebo-controlled, parallel group comparison of FlonaseTM nasal spray and Beconase AQ® nasal spray in patients with seasonal allergic rhinitis
FLN-443 IV A double-blind, placebo-controlled, parallel group comparison of FlonaseTM nasal spray and Beconase AQ® nasal spray in patients with seasonal allergic rhinitis
FLN-481 IV The effect of intranasal fluticasone propionate on the recovery of proinflammatory cytokines in the nasal secretions following allergen challenge
FLNL 62 IV A double-blind, double-dummy, parallel-group trial: fluticasone once daily versus loratadine once daily in pollinic rhinitis
FLPB0145 IV Comparison of fluticasone powder 1mg/day to budesonide powder 1mg/day in deterioration of severe asthma in children: a double-blind, randomised, multicentre study with parallel groups.
FLPB0256/FMS40175 IV Effect of long-term treatment with fluticasone propionate on bone density, growth and lung function in childhood asthma.
FLTA4004 IV Double-Blind, Double-Dummy, Randomized, Parallel-Group Comparison of the Efficacy and Safety Outcomes of Fluticasone Propionate Aqueous Nasal Spray Versus Encapsulated Loratadine Tablets Versus Placebo for Four Weeks in Subjects with Seasonal Allergic Rhinitis
FLTA4006 IV Double-blind, double-dummy, randomized, parallel group comparison of the efficacy and safety of fluticasone proprionate aqueous nasal spray vs encapsulated loratadine tablets vs a combination of fluticasone proprionate and loratidine vs placebo for two weeks in subjects with seasonal allergic rhinitis
FLTA4007 IV A double-blind, double-dummy, randomized, placebo-controlled, parallel-group comparison of fluticasone propionate aqueous nasal spray and triamcinolone acetonide aqueous nasal spray in subjects with seasonal allergic rhinitis
FLTA4008 IV A double-blind, double-dummy, randomized, placebo-controlled, parallel-group comparison of fluticasone propionate aqueous nasal spray and triamcinolone acetonide aqueous nasal spray in subjects with seasonal allergic rhinitis.
FLTA4021 IV A Randomized, Double-Blind, Parallel-Group, Comparative Trial Evaluating Fluticasone Propionate (220mcg BID), Triamcinolone Acetonide (600mcg BID), and Fluticasone Propionate (88mcg BID) in Combination with Salmeterol Xinafoate (42mcg BID), Each Delivered Via A Metered-Dose Inhaler, in Subjects with Asthma Who Remain Symptomatic Despite Receiving Inhaler Corticosteroids
FLTA4022 IV A Randomized, Double-Blind, Parallel-Group, Comparative Trial Evaluating Fluticasone Propionate (220mcg BID), Triamcinolone Acetonide (600mcg BID), and Fluticasone Propionate (88mcg BID) in Combination with Salmeterol Xinafoate (42mcg BID), Each Delivered Via A Metered-Dose Inhaler, in Subjects with Asthma Who Remain Symptomatic Despite Receiving Inhaled Corticosteroids
FLTA4024 IV Double-blind, double-dummy, randomized, parallel group comparison of fluticasone proprionate aqueous nasal spray versus encapsulated loratadine tablets versus a combination of fluticasone proprionate and loratadine versus placebo for two weeks in subjects with seasonal allergic rhinitis
FLTA4030 IV A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Comparative Study of Inhaled Fluticasone Propionate (88mcg BID) Versus Zafirlukast (20mg BID) in Subjects Who Are Currently Receiving Beta-Agonists Alone
FLTA4031 IV A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Comparative Study of Inhaled Fluticasone Propionate (88mcg BID) Versus Zafirlukast (20mg BID) in Subjects Who Are Currently Receiving Beta-Agonists Alone
FLTA4034 IV A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparative Study Of Inhaled Fluticasone Propionate 88mcg BID Versus Zafirlukast 20mg BID In Asthmatic Subjects Who Are Currently Receiving Low Dose Inhaled Corticosteroids
FLTA4035 IV A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparative Study Of Inhaled Fluticasone Propionate 88mcg BID Versus Zafirlukast 20mg BID In Asthmatic Subjects Who Are Currently Receiving Low Dose Inhaled Corticosteroids
FLTA4039 IV A randomized, double-blind, parallel group comparison study of inhaled fluticasone propionate (88mcg BID) versus montelukast sodium (10mg QD) in subjects currently receiving beta agonists alone.
FLTB4003 (FLUTI/AH94/K124) IV A comparison of the efficacy and tolerability of high dose inhaled fluticasone propionate via a metered-dose inhaler and the Volumatic spacer device with nebulised budesonide in adult asthmatics.
FLTB4009 IV A Study to Determine the Systemic Activity of a Single Dose of Fluticasone Propionate via the DiskusÔ in Asthmatic Children Inhaling at Different Inspiratory Flows
FMDT08 IV A single centre, randomised, open cross-over study to compare the handling and efficacy of fluticasone propionate 50mcg bd delivered via multi-dose powder inhaler (MDPI) or via Diskhaler in paediatric patients with asthma
FMS 40121 (FLU9405) IV A double blind, parallel group, two way study to compare a high starting dose of fluticasone (1000 µg/day) tapering off to a low maintenance dose (100 µg/day) and a continuous intermediate dose (200 µg/day) in asthmatic children aged 6 to 10 years.
FMS10001 (FLIT-ZAF) IV Fluticasone propionate versus Zafirlukast for the treatment of mild to moderate symptomatic asthma
FMS10026 IV A randomised, open-label, four-way crossover study to assess the relative systemic pharmacokinetics and absolute bioavailability of single inhaled and intravenous doses of fluticasone propionate and mometasone furoate in healthy subjects.
FMS40001 IV A randomised, double-blind, double-dummy, parallel group, multicentre study to compare the effect on growth measured by stadiometry of fluticasone propionate (100µg bd) administered via DISKUS™ with budesonide (200µg bd) administered via Turbuhaler in prepubescent children.
FMS40010 (MAG-MONTE) IV Comparing the efficacy of the antileukotriene montelukast to fluticasone 200µg in steroid naďve subjects with mild to moderate asthma.
FMS40012 IV Evaluation of the potential anti-inflammatory action of Leukotriene D4 receptor antagonists: comparison of Zafirlukast, an LDT4 receptor antagonist with low-dose fluticasone propionate, an inhaled steroid on sputum eosinophils in mild asthma
FMS40049 (FLIW04 519/120) IV Multi-centre, randomised, double-blind, parallel-group study to determine the clinical equivalence between fluticasone propionate 500µg once daily and fluticasone propionate 250µg twice daily, both delivered via the metered-dose-inhaler (MDI) in patients with moderate asthma.
FMS40243 IV A Comparison of the Pharmacokinetics and Pharmacodynamics of Inhaled Fluticasone Propionate in Healthy Volunteers and Subjects with Chronic Obstructive Pulmonary Disease
FNM10004 IV An open, three-period, balanced, incomplete block crossover study in healthy subjects to investigate the effect of 7 days co-administration of fluticasone propionate aqueous nasal spray (FPANS) with ritonavir, ketoconazole, or erythromycin on serum cortisol levels
FNM30030 IV A Double-Blind, Double-Dummy, Randomized, Parallel Group Comparison of 200mcg Fluticasone Propionate Aqueous Nasal Spray, Placebo and 10mg Encapsulated Loratadine Administered (No More than Once Daily) As-Needed in Subjects with Seasonal Allergic Rhinitis
FNM30031 IV A Double-Blind, Double-Dummy, Randomized, Parallel Group Comparison of 200mcg Fluticasone Propionate Aqueous Nasal Spray, Placebo and 10mg Encapsulated Loratadine Administered (No More than Once Daily) As-Needed in Subjects with Seasonal Allergic Rhinitis
FNM40017 IV A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Assess the Potential Growth Effects of a One-Year Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) Versus Placebo in Prepubescent, Pediatric Subjects with Perennial Allergic Rhinitis
FNM40027 (520/020 FLNT48) IV Intranasal fluticasone propionate 200µg once daily versus 200µg twice daily in severe ragweed allergic rhinitis.
FNM40108 (FP-IFA 1) IV Continuous therapy with fluticasone-nasal spray (200mg) versus oral cetirizine (10mg) in patients with seasonal allergic rhinitis: Comparison of effects of a pre- and coseasonal treatment on symptoms, quality of life and cytokines and mediators in nasal secretion.
FNM40138 (520/050, FLNL 24) IV Intranasal fluticasone propionate vs. beclomethasone dipropionate in the treatment of adult patients with perennial allergic rhinitis. A multi-centre, randomized, double-blind, parallel-group study.
FNM40181 IV A single centre, randomised, double blind, cross over study to investigate longitudinal growth using knemometry in children with seasonal and perennial rhinitis during treatment with fluticasone propionate aqueous nasal spray (FPANS) 100mcg/day and placebo.
FNM40188 IV An open study to evaluate the efficacy and tolerability of Flixonase ™ Aqueous Nasal Spray after switching from Rhinocort (Aqueous Nasal Spray or Turbuhaler) as a maintenance therapy for the treatment of perennial allergic rhinitis (PAR).
FNM40194 IV A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Two-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Subjects =15 Years Old with Seasonal Allergic Rhinitis (SAR)
FNM40195 IV A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Two-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Subjects =15 Years Old with Seasonal Allergic Rhinitis (SAR)
FNP40010 IV A single-centre, randomised, double-blind, parallel group study to determine the efficacy and tolerability of fluticasone propionate nasal drops (NASULES) 400mg twice daily, fluticasone propionate nasal drops (NASULES) 400mg once daily and placebo nasal drops in adult patients with bilateral polyposis.
FNP40013 IV A single –country, multicentre, open-label study to investigate the effect of Fluticasone Propionate nasal drops 800 mcg OD (divided between the nostrils) for 4 weeks on CT changes and the symptoms of nasal obstruction in the patients with nasal polyposis in preoperative period (Functional Endoscopic Sinus Surgery [FESS]).
FNP40014 IV A multi-centre, randomised, double-blind, parallel group study, to evaluate the efficacy and tolerability of fluticasone propionate nasal drops (Flixonase Nasule) 400 mcg twice daily and placebo in adult patients with nasal polyposis indicated for functional endoscopic sinus surgery (FESS) for a period of 6 months with a 12 months open label extension period.
FPD40001 IV A Comparison of fluticasone propionate (250µg bid) therapy via the new Diskus® dry powder inhaler to standard therapy (usual inhaled steroid via an alternate dry powder inhaler) in patients with moderate asthma.
FPD40012 IV A Randomized, Double-Blind, Double Dummy, Parallel Group Comparison of Fluticasone Propionate Inhalation Powder (50mcg BID) via DiskusTM with Oral Montelukast (5mg QD) Chewable Tablets in Children 6–12 years of Age with Persistent Asthma
FPD40013 IV A randomized, double-blind, double dummy, parallel group comparison of fluticasone propionate inhalation powder (50mcg BID) via DiskusTM with oral montelukast (5mg QD) chewable tablets in children 6–12 years of age with persistent asthma
FPD40014 IV A Randomized, Double-Blind, 12 Week, Comparative Trial of FP DISKUS 100mcg BID versus FP DISKUS 100mcg and Oral Montelukast 10mg QD in Adults with Persistent Asthma
FPD40015 IV A Randomized, Open-Label, Cross Over Trial, Assessing Ease of Use, Correctness of Use and Patient Preference of Fluticasone Propionate Inhalation Powder (100mcg BID) via the Diskus versus Fluticasone Propionate Aerosol via the Metered Dose Inhaler (88mcg BID) in Subjects at Least 12 Years of Age with Persistent Asthma Currently Receiving Short Acting Beta Agonists Alone
FPD40016 IV A Randomized, Open-Label, Cross Over Trial, Assessing Ease of use, Correctness of use and Patient Preference of Fluticasone Propionate Inhalation Powder (100mcg BID) via the DISKUS™ versus Fluticasone Propionate Aerosol via the Metered Dose Inhaler (88mcg BID) in Subjects at Least 12 Years of Age with Persistent Asthma Currently Receiving Short Acting Beta Agonists Alone.
India Flixonase PMS (no study number) IV Post Marketing Surveillance of Flixonase (Fluticasone Propionate Aqueous Nasal Spray (FPANS)) to Evaluate the Safety of Fluticasone 200 micrograms (mcg) Nasal Spray in Indian Patients with Allergic Rhinitis
NSG110341 IV A randomised, double blind, placebo controlled, 4 period, incomplete block, crossover study to assess the dose-response curve of intranasal fluticasone propionate (25, 50, 100 and 200 µg, once daily for 8 days) in the Vienna Challenge Chamber for the purpose of investigating the sensitivity of the model when evaluating glucocorticosteroids.
RES41102 IV A time-course study of the bronchoprotective effect of single dose inhaled fluticasone propionate 250 mg against adenosine 5’-monophosphate (AMP) challenge in mild asthma.
SAFP – PL01 / FMS 40266 IV An open multicentre, randomized study to assess quality of life and efficacy of two internationally - approved therapeutic regimens in patients with severe bronchial asthma
SLGF75 (FLIC 14) IV (Inhaled Fluticasone propionate and Salmeterol in sputum induced study in asthma) Salmeterol plus low-dose fluticasone propionate (FP) versus high-dose fluticasone propionate (FP) in naive patients with mild to moderate asthma: effects on pulmonary function, and inflammatory markers of induced sputum
WE50001 IV An Epidemiological Study of Overall Patterns of Use & Outcomes in Users of Fluticasone Propionate (Flonase) Nasal Spray
WEUK 1716 IV Pharmacoepidemiologic Analysis of the Impact of Regular Inhaled Corticosteroid (Ics) Use on Outcomes in Patients with Chronic Obstructive Pulmonary Disease (COPD)
WEUKBRE1156 / EPI#40468 IV Pneumonia and upper respiratory tract infections among COPD patients using fluticasone propionate/salmeterol in combination (ADVAIR®) versus other inhaled corticosteroids and bronchodilators alone
WEUS650 IV GPRD Cataract Study: Retrospective cohort study of cataract incidence among patients with Idiopathic Thrombocytopenic Purpura (ITP)
FLIC16 III A multicentre, randomised, double-blinded, parallel-group comparison of the efficacy and tolerability of fluticasone propionate 100mcg bid with nedocromil MDI 4mg bid in mild-moderate asthmatic children
FLNQ12 III A double blind, double dummy, placebo controlled trial of fluticasone propionate aqueous nasal spray and oral ketotifen in children with perennial rhinitis aged between 2 and 4 years.
FAP30001 III A Randomized, Double-Blind, Parallel-Group Trial of Inhaled Fluticasone Propionate/GR106642X 220mcg BID and 440mcg BID in Adolescent and Adult Subjects with Asthma
FAP30007 III A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Inhaled Corticosteroid Therapy
FAP30008 III A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Bronchodilator Therapy
FAP30010 III A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID versus Placebo in Propellant GR106642X in Pediatric Subjects 4 to 11 Years of Age With Asthma
FAP30011 III A multi-centre, randomised, double-blind, parallel group clinical trial to assess the efficacy and safety of fluticasone propionate/GR106642X 250mg BD compared with fluticasone propionate/propellants CFC 250mg BD administered by pressurised metered-dose inhaler in adult Chinese patients with asthma.
FAS30006 III A Multicentre, Randomised, Double-Blind, Parallel Group Clinical Trial to Compare the Efficacy and Safety of Fluticasone propionate (FP) 200mg/day with Fluticasone propionate 400mg/day Administered for 52 Weeks via a Multidose Powder Device (Diskusä) to Paediatric patients with Asthma.
FAS30007 III A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-Controlled Study to Determine the Efficacy and Safety of Fluticasone Propionate 200mcg/day Delivered for 12 Weeks via the BABYHALERTM in Paediatric Subjects Aged 12 to 47 Months with Recurrent/persistent Asthma-Like Symptoms BABYHALER™ is a trade mark of the GlaxoSmithKline group of companies
FAS30009 III A Multi-centre, Randomised, Parallel-Group, Open-Label Study to Assess the Long-Term Safety (Including Growth) of Fluticasone Propionate 100mcg bd via the Metered-Dose Inhaler and BabyhalerTM Spacer Device Compared With Sodium Cromoglycate 5mg qds Delivered via Metered Dose Inhaler and NebuhalerTM Spacer Device in Children aged 12-47 Months With Documented Evidence of Recurrent/Persistent Asthma-Like Symptoms over a 52-Week Treatment Period
FAS30030 III A Randomized (2:1), Stratified, Double-Blind, Parallel-Group, Placebo-Controlled, 12-week, Multi-Center Trial of Fluticasone Propionate HFA Inhalation Aerosol 88mcg BID versus Placebo HFA Delivered via an MDI and a Valved Holding Chamber with Facemask in Pediatric Subjects 1 to <4 Years of Age with Asthma
FCO 40004 (MD9706/ COPE) III Self-management of COPD, including self-treatment of exacerbations in an outpatient population.
FLIC06 III Inhaled Fluticasone Propionate in Asthmatic children. A multicentre, double-blind, double dummy, parallel group study to compare the efficacy and tolerability of inhaled fluticasone propionate 50mcg bid via metered dose inhaler (MDI) with sodium cromoglycate (DSCG) 10mg qds via metered dose inhaler (MDI) in asthmatic children with a clinical requirement for inhaled prophylaxis therapy.
FLIC09 III Nebulised Fluticasone propionate in an upper respiratory tract inflammatory disorder (rhinopharyngitis): a multicentre, randomised, blinded, parallel group study of the efficacy and safety of nebulised fluticasone propionate 0.5mg daily compared with nebulised beclomethasone dipropionate 0.8mg daily in children suffering from acute rhinopharyngitis.
FLIC15 III A multicenter, randomised, double-blind, parallel group study of the efficacy of fluticasone propionate (FP) diskus 100mcg/bid or 500mcg/bid to induce variations of eosinophils and of Eosinophil Cationic Protein (ECP) in serum and in sputum and to induce variations of exhaling nitric oxide (NO) in subjects with mild to moderate asthma
FLIC21 III A Multicentre, Randomised, Blinded, Parallel-Group Comparison of nebulised Fluticasone Propionate 250µg bid with nebulised Budesonide 500µg bid in asthmatic children.
FLIC22 III A multicentre, blinded, randomised, parallel group study to compare the efficacy and tolerability of nebulised fluticasone propionate 0.25mg bid versus nebulised beclomethasone dipropionate 0.40mg bid in children suffering from acute inflammatory conditions of the upper airways
FLIP20 III A Double-Blind, Parallel-Group Study to Investigate the Clinical Safety and Efficacy of Fluticasone Propionate, 50µg bd (100µg/day), Compared with Placebo in the Management of Moderately Severe Chronic Asthma in Children, Aged 6-12 Years
FLIP20 Extension III An Open Study to Assess the Long-Term Safety of Fluticasone Propionate 50µg bd (100µg/day) or 100µg bd (200µg/day) in Children, Aged 6-16 Years, with Moderately Severe Asthma
FLIP39 III A Multi-Centre, Randomised, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Fluticasone Propionate 50µg BD (100µg Daily) with Fluticasone Propionate 100µg BD (200µg Daily), Each Administered as a Dry Powder Formulation, in Children
FLIP51 III A Single-Centre, Randomised, Double-Blind, Three Way Crossover Study to Investigate Longitudinal Growth, Using Knemometry, in Children with Mild Asthma During Treatment with Beclomethasone Dipropionate 400µg bd (800µg/Day), Beclomethasone Dipropionate 200µg bd (400µg/Day) and Fluticasone Propionate 100µg bd (200µg/Day)
FLIP58 III A multi-centre, randomised, double-blind, double-dummy, parallel-group study to compare the efficacy and safety of fluticasone propionate 400mg daily with budesonide 400mg daily in children with asthma.
FLIQ46 III A multicentre, randomised, double-blind, double-dummy, parallel group clinical trial to determine the clinical equivalence between fluticasone propionate 400µg/daily via the DiskusTM and budesonide 800µg/daily via the TurbuhalerTM administered for 5 months in pre-pubescent children aged 4 to 12 years, inclusive, with asthma.
FLIS03 III A single centre double blind, double dummy cross-over study to investigate urinary cortisol metabolites, bone metabolism markers and growth in asthmatic children treated with inhaled steroids.
FLIS04 III A single-centre, double-blind, double dummy, randomised cross-over study to compare the effectiveness of fluticasone propionate (FP), oral prednisolone and placebo in the prevention of viral-induced asthma in children.
FLIS09 III A study to investigate the effectiveness of fluticasone propionate (FP) 200 mg/day versus beclomethasone dipropionate (BDP) 400 mg/day delivered via the Babyhaler™ spacer device in patients with a history of wheeze aged 2 to 18 months.
FLIT 72 (Long-Term Follow-Up) III A multicentre, randomised, double-blind, parallel group, six-week study to compare the efficacy and safety of fluticasone propionate 500mcg daily via the metered dose inhaler and via the Diskhaler inhaler with beclomethasone dipropionate 1000mcg daily via the metered dose inhaler followed by a 46-week assessment of the tolerance to fluticasone propionate 500mcg daily via the metered dose inhaler and beclomethasone dipropionate 1000mcg daily via the metered dose inhaler in patients with chronic asthma (results of the 46 week safety study)
FLIT 72 Short term III A Multicentre, Randomised, Double-Blind, Parallel Group, Six-Week Study To Compare The Efficacy and Safety of Fluticasone Propionate 500µg Daily via the Pressurised Inhaler and via the Diskhaler™ Inhaler with Beclomethasone Dipropionate 1000µg Daily via the Pressurised Inhaler in Patients with Moderately Severe Chronic Asthma
FLIT12 – Part 1 III A Multicentre, Double-Blind, Randomised, Four-Week, Parallel-Group Study to Compare the Efficacy of, and Tolerance to, Fluticasone Propionate, 100µg bd (200µg/day), Administered Via the Metered-Dose Inhaler or as a Dry Powder Via the Diskhaler™ Inhaler in Adult Patients with Mild to Moderate Asthma
FLIT12- Part 2 III Multicentre, Open 12-Month Study to Assess the Tolerance of Fluticasone Propionate Dry Powder Administered Via the Powder Inhaler at Doses Between 100µg bd (200µg/day) and 500µg bd (1000µg/day) in Adult Patients with Mild to Moderate Asthma
FLIT14 – Part 1 III A Multicentre, Double-Blind, Randomised, Four-Week, Parallel-Group Comparison of Fluticasone Propionate 100µg bd (200µg/day) with Beclomethasone Dipropionate 200µg bd (400µg/day) in Adult Patients with Mild to Moderate Asthma
FLIT14 - Part 2 III A Multicentre, Open 12-Month Study to Assess the Tolerance of Fluticasone Propionate Administered Via the Pressurised Inhaler at Doses Between 100µg bd (200µg/day) and 500µg bd (1000µg/day) in Adult Patients with Mild to Moderate Asthma
FLIT18 (FNM30019) III Fluticasone propionate aqueous nasal spray 200mcg once daily vs. 100mcg twice daily in ragweed allergic rhinitis in a multicentre, double-blind, placebo-controlled, parallel group study.
FLIT22 (FNM30029) III A parallel group comparison of fluticasone propionate aqueous nasal spray (FPANS) with placebo in patients with non-seasonal allergic rhinitis with symptoms all year round.
FLIT25 III A Multicentre, Randomised, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Fluticasone Propionate 1mg bd (2mg Daily) Administered by Pressurised Inhaler with that of Fluticasone Propionate 1mg bd (2mg Daily) Administered as a Dry Powder Via a Diskhaler Inhaler and an Open Assessment of the Long-Term Tolerance to, and Safety of, Fluticasone Propionate 1mg bd (2mg Daily) Administered as a Dry Powder Via a Diskhaler Inhaler
FLIT26 III A Multicentre, Double-Blind, Parallel-Group Study to Compare the Long-Term Efficacy and Safety of Fluticasone Propionate 750µg bd (1500µg Daily) with Beclomethasone Dipropionate 750µg bd (1500µg Daily) in Patients with Severe Asthma
FLIT35 III A Multicentre, Double-Blind, Randomised, Six-Week, Parallel-Group Study to Compare the Efficacy and Safety of Fluticasone Propionate 500µg bd (1000µg Daily) with Beclomethasone Dipropionate 1000µg bd (2000µg Daily) in Adult Patients with Severe Asthma
FLIT37 III A Multicentre, Randomised, Double-Blind, Parallel-Group Study to Compare the Safety and Efficacy of Fluticasone Propionate 750µg bd (1500µg/Day) with that of Beclomethasone Dipropionate 750µg bd (1500µg/Day) in Geriatric Patients with Chronic Asthma
FLIT40 III A Multicentre, Randomised, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Fluticasone Propionate 100µg bd (200µg Daily) with Beclomethasone Dipropionate 200µg bd (400µg Daily) Administered Via a Pressurised Inhaler in the Management of Childhood Asthma
FLIT85 III A multicenter, randomized, double-blind, placebo controlled study to compare the efficacy and safety of fluticasone propionate dry powder 200mcg daily via a Diskhaler inhaler and fluticasone propionate 100mcg daily via a Diskhaler inhaler in comparison with placebo dry powder via a Diskhaler inhaler in children with asthma.
FLIT92 III A multicentre, randomised, double-blind, parallel-group study to compare the efficacy and tolerability of fluticasone proprionate 100mg bd administered by pressurised inhaler propelled by a mixture of propellants 11 and 12 or by an alternative propellant, GR106642X for a period of one month in adult patients with mild to moderate reversible airways obstruction
FLIT93 III A multicentre, randomised, double-blind, parallel group study to compare the efficacy and tolerability of fluticasone propionate (250 mg bd) administered by pressurised inhaler propelled by a mixture of propellants 11 and 12 or by an alternative propellant, GR106642X in adult patients with mild to moderate reversible airways obstruction
FLIT94 (Study Report GRP/95/004V2) III A multicentre, randomised, double-blind, parallel-group study to compare the efficacy and tolerability of fluticasone propionate 500 µg bd administered by pressurised inhaler propelled by a mixture of propellants 11/12 or by an alternative propellant GR106642X for a period of three months in adult patients with chronic reversible airways obstruction
FLIT94 (Study report GRP/95/030) III A multicentre, randomised, double-blind, parallel-group study to compare the efficacy and tolerability of fluticasone propionate 500 µg bd administered by pressurised inhaler propelled by a mixture of propellants 11/12 or by an alternative propellant GR106642X for a period of twelve months in adult patients with chronic reversible airways obstruction.
FLIT96 III A multicentre, randomised, double-blind, crossover study to compare the efficacy and tolerability of fluticasone propionate 2 mg daily administered by pressurised inhaler propelled by a mixture of propellants 11/12 or by an alternative propellant, GR106642X in adult patients with severe reversible airways obstruction.
FLIT97 III A multi-centre, randomised, double-blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000mg daily with placebo in chronic obstructive pulmonary disease
FLIT98 (report no: GRP/96/006 III Inhaled fluticasone propionate in an acute exacerbation of chronic obstructive pulmonary disease: a multi-centre, randomised, double-blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 2000 µg daily compared with placebo in chronic obstructive pulmonary disease (chronic bronchitis)
FLIT99 III A double-blind, randomised, parallel group, placebo-controlled study of inhaled fluticasone propionate delivered via the Babyhaler™ in the prevention of post-bronchiolitic respiratory symptoms in infants.
FLIT-CN02 III An open, multicenter, randomized, parallel group study to compare the efficacy and safety of local manufactured fluticasone propionate with imported fluticasone propionate in the treatment of patients with moderate to severe asthma.
FLN-204 III A double-blind, randomized, placebo-controlled study of the efficacy and safety of once- versus twice-daily intranasal administration of aqueous fluticasone propionate for four weeks in adult patients with seasonal allergic rhinitis
FLN-260 III A double-blind, placebo-controlled, dose-tolerance study to assess the effects of fluticasone propionate aqueous nasal spray versus oral prednisone on the HPA axis
FLN-270 III A double-blind, randomized, placebo-controlled, parallel group study comparing fluticasone propionate aqueous nasal spray 200µg QD manufactured with two different procedures in patients with seasonal allergic rhinitis
FLN-301 III A double-blind, randomized, placebo-controlled study of the efficacy and safety of fluticasone propionate aqueous 200mcg QD versus beclomethasone aqueous 168mcg BID versus placebo by intranasal administration for two weeks in adult patients with seasonal allergic rhinitis in the mountain cedar season
FLN-305 III A double-blind, randomized, placebo-controlled study of the efficacy and safety of aqueous fluticasone propionate given once- versus twice-daily versus placebo for two weeks in adolescent patients with seasonal allergic rhinitis
FLN-306 III A double-blind, randomized, placebo-controlled study of the efficacy and safety of aqueous fluticasone propionate given once- versus twice-daily versus aqueous beclomethasone dipropionate versus placebo for four weeks in adult and adolescent patients with seasonal allergic rhinitis
FLN-310 III A double-blind, randomized, parallel group, mutlicenter, placebo-controlled clinical trial to evaluate the safety and efficacy of once-daily versus twice-daily intranasal administration of aqueous fluticasone propionate in patients with perennial allergic rhinitis.
FLN-311 III A double-blind, randomized, parallel group, multicenter, placebo-controlled clinical trial to evaluate the safety and efficacy of once-daily versus twice-daily intranasal administration of aqueous fluticasone propionate versus aqueous beclomethasone dipropionate in patients with perennial allergic rhinitis.
FLN-320 III A double-blind, randomized, placebo-controlled study of the efficacy and safety of aqueous fluticasone propionate given once daily versus placebo for two weeks in pediatric patients with seasonal allergic rhinitis
FLN321 III A double-blind, randomized, placebo-controlled study of the efficacy and safety of aqueous fluticasone propionate versus placebo for four weeks in pediatric patients with seasonal allergic rhinitis.
FLN-350 III A double-blind, randomized, placebo-controlled study of the efficacy and safety of two doses of fluticasone propionate aqueous nasal spray given twice daily versus placebo for four weeks in patients with perennial nonallergic rhinitis
FLN-351 III A double-blind, randomized, placebo-controlled study of the efficacy and safety of fluticasone propionate aqueous nasal spray given twice daily versus placebo for four weeks in patients with perennial nonallergic rhinitis
FLN-402 III A double-blind, double-dummy, randomized, parallel group comparison of the efficacy and safety of fluticasone propionate aqueous nasal spray 200mcg QD versus terfenadine 60mg BID versus placebo for four weeks in patients with seasonal allergic rhinitis
FLN-444 III A double-blind, placebo-controlled, randomized, parallel-group park study to compare the onset of action of fluticasone propionate aqueous nasal spray 200mg QD versus beclomethasone dipropionate aqueous nasal spray 168mg BID in patients with seasonal allergic rhinitis.
FLN-445 III A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Park Study to Compare the Onset of Action of Fluticasone Propionate Aqueous Nasal Spray 200µg QD Versus Beclomethasone Dipropionate Aqueous Nasal Spray 168µg BID in Patients with Seasonal Allergic Rhinitis
FLNC02 III A double blind comparison of Fluticasone Propionate aqueous nasal spray, Levocabastina nasal spray and placebo in the treatment of patients with seasonal rhinitis to grass pollen.
FLNC04 III Multicentre, Randomised, Double-blind, parallel group study to evaluate the efficacy of fluticasone propionate aqueous nasal spray associated with antibiotic therapy in the treatment of patients with acute rhino-sinusitis.
FLNL07 III Fluticasone propionate aqueous nasal spray treatment for perennial allergic rhinitis in children.
FLTA2008 Open-Label Extension III Open-Label Extension of a Randomized, Double-Blind, Parallel-Group Trial Assessing the Efficacy and Safety of FIuticasone Propionate via the Multi-Dose Powder Inhaler 100mcg BID, 200mcg QD, and Placebo in Subjects Aged 4 to 11 Years With Chronic Asthma
FLTA2016 III A stratified, randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate via the multi-dose powder inhaler 100mcg QD, 200mcg QD, 500mcg QD and placebo in adolescent and adult subjects with chronic asthma.
FLTA3001 III A Randomized, Double-Blind, Parallel-Group Trial to Assess the Long Term Safety of Fluticasone Propionate Inhalation Aerosol 100mcg BID and 500mcg BID Versus Placebo BID in Adult Subjects with Moderate Asthma
FLTA3010 III A double-blind, randomized, placebo-controlled study of the efficacy and safety of fluticasone propionate aqueous nasal spray versus placebo followed by a six-month open-label safety extension in subjects with perennial nonallergic rhinitis
FLTA3014 III A Randomized, Double-Blind, Comparative Trial of Inhaled Fluticasone Propionate 250mcg BID With and Without a Spacer Device to Inhaled Fluticasone Propionate 100mcg BID Without a Spacer Device and Placebo With and Without a Spacer Device in Adolescent and Adult Subjects with Asthma
FLTA3014 PK III Pharmacokinetic Report: A Randomized, Double-Blind, Comparative Trial of Inhaled Fluticasone Propionate 250mcg BID With and Without a Spacer Device to Inhaled Fluticasone Propionate 100mcg BID Without a Spacer Device and Placebo With and Without a Spacer Device in Adolescent and Adult Subjects With Asthma
FLTA3020 III A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Comparative Trial of Inhaled Fluticasone Propionate 110mcg BID and 220mcg BID via Metered-Dose Inhaler Propelled by Propellants 11/12 or by GR106642X in Adolescent and Adult Subjects with Asthma
FLTA3022 III A Randomized, Double-Blind, Placebo-Controlled Comparative Trial of Fluticasone Propionate 440mcg BID or 880mcg BID versus Placebo Administered via Metered-Dose Inhaler in Propellant 11/12 or GR106642X in Adolescent and Adult Oral Corticosteroid Dependent Asthmatics.
FLTA3025 III A randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate 250mcg BID, 500mcg BID, and placebo BID via the DISKUS in subjects with chronic obstructive pulmonary disease (COPD).
FLTA-4025 III A randomized, double-blind, placebo-controlled study examining the effect of fluticasone propionate aqueous nasal spray 200mcg QD used in conjunction with an antibiotic in allergic and nonallergic subjects with recurrent sinusitis
FLTA4033 III A randomized, double-blind, placebo-controlled study examining the effect of fluticasone propionate aqueous nasal spray 200µg QD in subjects with an acute episode of recurrent sinusitis
FLTB 3051 III Report on a multicentre, randomised, double-blind, parallel-group clinical trial to compare the efficacy and safety of the dry powder formulation of fluticasone proprionate (FP) 200mg/day with fluticasone proprionate 400mg/day administered for 6 weeks from a multidose powder device (Diskus™) to paediatric patients with chronic asthma
FLTB3001 III A multicentre, randomised, double blind, parallel group study to compare the oral steroid-sparing effect of nebulised fluticasone propionate 2mg twice daily and 0.5mg twice daily with placebo in patients with chronic severe asthma.
FLTB3002 III A multicentre, randomised, double-blind, parallel group clinical trial to determine the safety and efficacy of nebulised fluticasone propionate 1mg twice daily compared with oral soluble prednisolone administered for 7 days to children aged 4 to 16 years with an acute asthma exacerbation.
FLTB3013 III A multi-centre, randomised, double-blind, parallel-group clinical trial to compare the safety and efficacy of the dry powder formulation of fluticasone propionate 400mg/day and beclomethasone dipropionate 400mg/day administered for 12 weeks to paediatric patients with chronic asthma.
FLTB3014 III A multicenter, randomised, double-blind, double-dummy, parallel group clinical trial to determine the safety and efficacy of inhaled fluticasone propionate 500 mg bd metered dose inhaler with a Volumatic™ spacer compared to oral soluble prednisolone administered for 7 days to patients aged 4 to 16 years inclusive, with an acute asthma exacerbation.
FLTB3015 III A multi-centre, randomized, double-blind, parallel-group clinical trial to compare the safety and efficacy of the dry powder formulation of fluticasone propionate 400mg/day and beclomethasone dipropionate 400mg/day administered for 52 weeks to paediatric patients with chronic asthma
FLTB3016 III A multi-centre, randomised, double-blind, placebo-controlled parallel group study to determine the efficacy and safety of inhaled fluticasone propionate 50mg bd and 100mg bd delivered via the Babyhaler™ spacer device in the management of asthma symptoms in children aged 12-47 months inclusive.
FLTB3017 III A multi-centre, randomised, double-blind, placebo-controlled parallel group study to determine the efficacy and safety of inhaled fluticasone propionate 100mg bd and 250mg bd delivered via the Babyhaler™ spacer device in the management of asthma symptoms in children aged 12–47 months inclusive.
FLTB3021 III A double-blind, double-dummy, randomised, parallel group study to evaluate the early substitution of nebulised fluticasone propionate (FP) 2mg twice daily (bd) for oral prednisolone 50mg once daily (od) during the early recovery period after an acute exacerbation of asthma in adult patients.
FLTB3026 III A single centre, randomised, double-blind, cross-over study to determine the effects of fluticasone propionate (Flixotideä) 500µg BD delivered via the MDI and spacer compared with placebo on the cellular and cytokine characteristics of induced sputum in subjects with chronic obstructive pulmonary disease.
FLTB3030 III A phase III, multi-centre, double-blind, randomised, cross-over group study to evaluate the efficacy and safety of fluticasone propionate Nebules 0.5mg twice daily compared with placebo in the treatment of symptomatic asthma in children under 4 years of age.
FLTB3031 III A randomised, double-blind, parallel-group clinical trial to establish the safety and efficacy of nebulised fluticasone propionate 1mg twice daily compared with oral prednisolone administered for 7 days to pre-school children aged 48 months or less with an acute exacerbation of asthma.
FLTB3036/FLIP56 III A single-centre, randomised, double-blind, parallel group study to investigate the effects of high-dose inhaled corticosteroid therapy on bone mass in adult patients with moderately severe asthma
FLTB3047 and FLTB3047 Addendum III A Multi-centre, Randomised, Double Blind, Parallel Group Clinical Trial to Assess the Efficacy and Tolerability of Fluticasone Propionate/GR106642X 100mcg bd Compared with Fluticasone Propionate/Propellants 11 and 12 100mcg bd Administered by Pressurised Metered-Dose Inhaler in Paediatric Patients with Asthma for 4 Weeks.
FLTB3048 III A Multi-Centre, Randomised, Double-Blind Parallel Group Clinical Trial to Assess the Long-Term (52 Weeks) Safety of Fluticasone Propionate 500mcg BD Administered by Pressurised Metered Dose Inhaler Propelled by GR106642X Propellant in Comparison with Propellants 11 and 12 in Adolescent and Adult Subjects with Asthma
FLTB3049 III A phase III, randomised, double-blind, parallel group study to compare the efficacy of inhaled fluticasone propionate 100mg given once daily and fluticasone propionate 50mg given twice daily, both delivered via the multi-dose powder inhaler, in children aged 4–16 years with mild to moderate, stable asthma.
FLTB3052 III A Multicentre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study Examining the Effect of Fluticasone Propionate Aqueous Nasal Spray (200µg once daily (od)) as an Adjunct to Antibiotic Therapy in Subjects with Recurrent Sinusitis.
FLTB3053 III A multicentre, randomised, double-blind, placebo-controlled, parallel group study examining the effect of fluticasone propionate aqueous nasal spray (200µg once daily [od]) as an adjunct to antibiotic therapy in subjects with recurrent sinusitis.
FLTB3054 (FLIT78) [ISOLDE] III A multicentre, double-blind, placebo-controlled, parallel group study of the efficacy and tolerability of long-term inhaled fluticasone propionate 500mg twice daily via a Volumatic Spacer device in patients with non-asthmatic chronic obstructive pulmonary disease, including an acute oral corticosteroid trial.
FLTB3055 III A double blind, double dummy, crossover study to compare the systemic pharmacodynamic effects and safety of inhaled fluticasone propionate Nebules™ 1mg bd with oral prednisolone administered for 7 days to children aged 4 to 16 years with asthma.
FLTF3003 III A multicentre, randomised, double-blind, parallel group, controlled versus placebo, eight month study, to evaluate efficacy and tolerability of fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis in adults.
FLUPD AH90 N081 III A phase III multicentre, open, parallel-group, randomised study to compare the efficacy and tolerability of fluticasone propionate 50 micrograms bd via the Diskhaler™ with inhaled sodium cromoglycate (Intal) 20 milligrams qds via the Spinhaler in asthmatic children with a clinic requirement for inhaled prophylactic therapy.
FLUTI/AH89/F079 III A phase III, multicentre, open-label, parallel-group study to compare the efficacy and tolerability of fluticasone propionate 100 micrograms bd with budesonide 200 micrograms bd administered via a metered-dose inhaler in adult patients with mild to moderate asthma.
FLUTI/AH89/J78 III A phase III, multi-centre, open-label, parallel group study to compare the efficacy and tolerability of fluticasone propionate 500 micrograms bd with budesonide 600 micrograms bd administered via a metered dose inhaler in adult patients with moderate to severe symptomatic asthma.
FLUTI/AH92/N114 III A phase III, multi-centre, double-blind, parallel group study to compare the efficacy and tolerability of a high dose step-down treatment regimen of fluticasone propionate (2.0mg reducing to 0.5mg daily) with a fixed dose of fluticasone propionate (0.5mg daily) in maintaining the control achieved following oral corticosteroid therapy for an acute severe exacerbation of asthma in adult patients.
FMDT01 (Report No. GRP/94/021) III A multi-centre, randomised, double-blind, double-dummy, parallel-group study to determine the clinical equivalence between fluticasone propionate 50µg twice daily delivered via a multidose powder inhaler (MDPI) and the Diskhaler™ in children aged 4-11 years with reversible airways disease
FMDT02 III A multi-centre, randomised, double-blind, double-dummy, parallel-group study to determine the clinical equivalence between fluticasone propionate 100mg twice daily delivered via a multidose powder inhaler (MDPI) and the Diskhaler™ in adult and paediatric patients with reversible airways disease.
FMDT03 III A multicentre, randomised, double-blind, double-dummy, parallel-group study to determine the clinical equivalence between fluticasone propionate 250mg twice daily delivered via a multidose powder inhaler (MDPI) and the Diskhaler in adult patients with reversible airways disease.
FMDT04 (Report No. GRP/94/024) III A multi-centre, randomised, double-blind, double-dummy, parallel-group study to determine the clinical equivalence between fluticasone propionate 500µg twice daily delivered via a multidose powder inhaler (MDPI) and the Diskhaler™ in adult patients with moderate to severe reversible airways disease
FMS30002/FLU9611 III A multi-centre, randomised, double-blind, parallel group study to validate the changes in tidal breathing lung function parameters versus FEV1 and PD20 assessments due to anti-inflammatory treatment in 5 to 10 years old mild to moderately symptomatic children with asthma.
FMS30058 III A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 12-Week Study of Fluticasone Propionate 44mcg BID and 88mcg BID Delivered via CFC MDI and a Valved Holding Chamber With Facemask in Subjects With Asthma Age 24 Months to 47 Months
FMS30059 III A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 12-Week Study of Fluticasone Propionate 44mcg BID and 88mcg BID Delivered via CFC MDI and a Valved Holding Chamber With Facemask in Subjects With Asthma Age 6 Months to 23 Months
FMS30060 [FLU9901, AIR] III Anti-inflammatory treatment of infants with persistent dyspnoea (Early Wheezing).
FMS40166 (FLU9101, ECHO) III A general practice, single-centre, randomised, double-blind, placebo controlled parallel group study to determine the effect of 2 weeks treatment with fluticasone propionate 2 x 250 mcg bd MDI via Volumatic spacer in patients with persistent cough and/or acute bronchitis.
FMS40180/FLU9520 III A placebo controlled trial studying the effect of a single dose inhaled fluticasone propionate on the bronchial diameter and the severity of exercise-induced asthma.
FMS40185/FLU9105 III A comparative study of the effects of fluticasone propionate (FP) and beclomethasone dipropionate (BDP) on non-specific bronchial hyperresponsiveness.
FMS40229/FLU8810 III Efficacy of treatment with inhaled fluticasone and the effect of priming and activation of PMN cells in children with allergy and asthma.
FMS40230/FLIT67 III A multicentre, randomised, double-blind, parallel group, 12 month study to compare the safety and tolerability of fluticasone propionate 500mcg twice daily with beclomethasone dipropionate 1000mcg twice daily administered via the pressurised inhaler in adults with severe chronic asthma
FMS40240 (FLIT76). III A multicentre, randomised, double-blind, double-dummy, parallel-group, six-week study to compare the efficacy and safety of fluticasone propionate 1000µg and 2000µg daily with budesonide 1600µg daily, all via pressurised inhaler, in patients with severe chronic asthma.
FMS40256 [FLU9705, Asterisk] III FLU9705: a multi-centre, parallel group, randomised, double-blind study to investigate the efficacy of fluticasone propionate 100 mcg MDI bd versus placebo MDI bd both via Babyhaler™ spacer in 1 to 5 year old children with asthma or asthma-like symptoms during a 6 months study period.
FMS40257 [FLU9903, Sjokola] III Treatment with inhaled corticosteroids in wheezing pre-school children: is there a predictable effect?
FNB30001 III A single centre, randomised, double blind, parallel group study to compare the efficacy of nebulised Fluticasone Propionate 2 mg twice daily (bd) with placebo in patients with moderate to severe chronic obstructive pulmonary disease.
FNLN44/FN9312 III A single-centre, randomised, double-blind, parallel group study to determine the efficacy and tolerability of fluticasone propionate aqueous nasal spray 100 mcg four times daily, fluticasone propionate aqueous nasal spray 200 mcg four times daily and placebo aqueous nasal spray four times daily in adult patients with nasal polyps/ chronic sinusitis.
FNM 40079 III A study to investigate the effect of intranasal fluticasone propionate in more detail during nasal allergen provocation in patients with an isolated grass pollen allergy.
FNM30015/FLIP07 III A dose-ranging, parallel-group study comparing fluticasone propionate aqueous nasal spray 50mcg, 100mcg, 200mcg and 400mcg twice daily with placebo in patients with perennial rhinitis.
FNM30016 (FLNS07) III A single-centre, randomised, double-blind, parallel group study to determine the efficacy and tolerability of fluticasone propionate aqueous nasal spray 200µg twice daily, beclomethasone dipropionate aqueous nasal spray 200µg twice daily and placebo aqueous nasal spray administered twice daily in adult patients with bilateral polyposis.
FNM30020 (FLIT17) III A double-blind, placebo-controlled, parallel group comparative study to assess the safety and efficacy of fluticasone propionate aqueous nasal spray, 200mcg given once daily, with beclomethasone dipropionate aqueous nasal spray, 200mcg given twice daily, in the treatment of seasonal rhinitis.
FNM30021 (FLIT 11) III A double-blind, parallel-group study to assess the safety of long-term use of fluticasone propionate aqueous nasal spray (200mcg given twice daily) compared with beclomethasone dipropionate aqueous nasal spray (200mcg given twice daily) in the treatment of perennial rhinitis.
FNM30033 III A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of a Four-Week Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) on Ocular Symptoms Commonly Associated with Allergic Rhinitis
FNM30034 III A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of a Four-Week Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) on Ocular Symptoms Commonly Associated with Allergic Rhinitis
FNM40001 III A multi-centre, randomised, double blind, placebo controlled, parallel group study examining the effect of fluticasone propionate aqueous nasal spray (200mcg od) and/or inhaled fluticasone propionate (250mcg bd) in pollen induced asthma and rhinits.
FNM40044/FN9413 III A study to investigate the effect of intranasal fluticasone propionate in more detail during nasal allergen provocation in patients with an isolated grass pollen allergy.
FNM40054/FN9504 III A placebo controlled trial during the pollen season comparing the effects of intranasal beclomethasone dipropionate and fluticasone propionate in children and young adults with asthma and allergic rhinitis.
FNM40072 III Intranasal Fluticasone Once Daily Compared with Once-Daily Cetirizine in the Treatment of Seasonal Allergic Rhinitis.
FNM40083 (FLNQ03) III Intranasal fluticasone proprionate does not prevent acute otitis media during viral upper respiratory infection in children.
FNM40137 (FLNL39) III The common cold: Effects of intranasal fluticasone propionate treatment.
FNM40173 (FLNT59) III Intranasal fluticasone propionate vs loratadine in the treatment of adolescent patients with seasonal allergic rhinitis.
FNM40178 III A double blind, parallel armed, randomised, controlled trial into the non-surgical management of adenotonsillar hypertrophy.
FNM40183 III A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Potential Effects of a Six-Week Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) on the HPA-Axis in ł2 and <4 Year Old Subjects with Allergic Rhinitis.
FNM40184 III A Multicenter, randomized, double-blind, parallel-group study examining the effect of fluticasone propionate aqueous nasal spray 200mcg QD in subjects with sinus pain and pressure associated with nasal congestion due to allergic rhinitis
FNM40185 III A multicenter, randomized, double-blind, parallel group study examining the effect of fluticasone proprionate aqueous nasal spray 200mcg QD in subjects with sinus pain and pressure associated with nasal congestion due to allergic rhinitis
FNP30002 III Single-centre, randomised, double-blind study to determine the efficacy (and tolerability) of fluticasone propionate nasal drops 400mg OD and placebo in adult patients with nasal polyps or chronic sinusitis.
FPD40009 III A Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250mcg QD) and Placebo in Subjects at Least 12 Years of Age with Chronic Asthma Currently Receiving Short Acting Beta Agonist Alone
FPD40010 III A Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250mcg QD) and Placebo in Subjects at Least 12 Years of Age with Chronic Asthma Currently Treated with Inhaled Corticosteroids
R1810198 III An actual use study in support of the over-the-counter switch of Flonase Allergy
R1810220 III An efficacy and safety study of fluticasone propionate (FP) aqueous nasal spray in subjects with perennial allergic rhinitis (PAR)
R1810221 III An efficacy and safety study of fluticasone propionate (FP) aqueous nasal spray in subjects with seasonal allergic rhinitis (SAR)
UCR/94/025FLN-261 III A double-blind, placebo-controlled trial to assess the safety of long-term treatment with fluticasone proprionate aqueous nasal spray
EL110002 II A single-centre, randomised, double-blind, double-dummy, placebo-controlled, 3-period crossover study to evaluate the effect of pre-treatment with repeat doses of a new chemical entity (NCE) on the allergen-induced late asthmatic response in subjects with mild to moderate asthma, using fluticasone propionate (250 mg twice daily for 7 days) as a positive control.
FFA10022 II A randomised, double-blind, placebo-controlled, incomplete block, 3-way cross-over study to investigate the effect of repeat inhaled doses of GW685698X and FP on airway responsiveness to adenosine 5’-monophosphate (AMP) in mild asthmatic patients
FLI-201 II A Randomized, Double-Blind Comparative Trial of Three Dosage Regimens of Inhaled Fluticasone Propionate Versus Placebo in Adult Patients with Asthma
FLIP01 II Inhaled Fluticasone Propionate for the Treatment of Moderately Severe Asthma in Patients Not Already Taking Inhaled Steroids. A Dose-Ranging Study and Comparison with Inhaled Beclomethasone Dipropionate.
FLIP04 II A Multicentre, Double-Blind, Randomised, Four-Week, Parallel-Group, Comparison of Inhaled Fluticasone Propionate and Inhaled Beclomethasone Dipropionate in Patients with Severe Asthma Controlled by High-Dose Inhaled Corticosteroids
FLIP63 II A single-centre, double-blind study to investigate the effects of inhaled fluticasone propionate (FP) 1500mcgdaily on inflammatory processes in the lungs of patients with chronic obstructive airways disease.
FLIT05 II A Multicentre, Four-Week, Double-Blind, Parallel-Group Comparison of Fluticasone Propionate (50µg, 100µg, 200µg, and 400µg bd) with Beclomethasone Dipropionate (200µg bd) in Patients with Moderately Severe Asthma
FLIT06 (FNM30024) II Fluticasone propionate aqueous nasal spray, 200mcg twice daily, versus beclomethasone dipropionate aqueous nasal spray, 200mcg twice daily, in seasonal rhinitis. A multicentre, placebo-controlled, double-blind, parallel-group study.
FLN-202 II A double-blind, randomized, placebo-controlled dose-ranging study of the efficacy and safety of twice-daily intranasal administration of aqueous fluticasone propionate in adult patients with seasonal allergic rhinitis.